Have a personal or library account? Click to login
Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman’s disease: a single medical center study in Tunisia Cover

Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman’s disease: a single medical center study in Tunisia

Open Access
|Mar 2024

References

  1. CASTLEMAN B, IVERSON L, MENENDEZ VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956 Jul–Aug;9(4):822-30.
  2. GABA AR., STEIN RS., SWEET DL., VARIAKOJIS D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978 Jan;69(1):86-90.
  3. MUNSHI N., MEHRA M., VAN DE VELDE H., DESAI A., POTLURI R., VERMEULEN J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015 May;56(5):1252-6.
  4. BONEKAMP D., HORTON KM., HRUBAN RH., FISHMAN EK. Castleman disease: the great mimic. Radiographics. 2011 Oct;31(6):1793-807.
  5. CRONIN DM., WARNKE RA., Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009 Jul;16(4):236-46.
  6. MARIA MARTA BIANCHI, FRANCISCO JAVIER, NARVAEZ GARCIA, PILAR SANTO, VALERIA RIOS-RODRIGUEZ, DIANA DE LA FUENTE., et al. Maladie de Castleman multicentrique mimant une maladie de Still de l’adulte. Revue Du Rhumatisme. 2009; 76(5) : 471–474.
  7. KELLER AR., HOCHHOLZER L., CASTLEMAN B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972 Mar;29(3):670-83.
  8. TALAT N, BELGAUMKAR AP, SCHULTE KM. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg. 2012 Apr;255(4):677-84.
  9. J. YILDIZ., M. BAGCI., S. SAYIN., A. KAYA., F. YILMAZ., O. EKINCI., et al. The clinicopathological features and survival of Castleman disease: A multicenter Turkish study. Eur Rev Med Pharmacol Sci. 2022 Feb;26(4):1131-1137.
  10. PRIBYL K., VAKAYIL V., FAROOQI N., ARORA N., KREITZ B., IKRAMUDDIN S., et al. Castleman disease: A single-center case series. Int J Surg Case Rep. 2021;80:105650.
  11. HAAP M., WIEFELS J., HORGER M., HOYER A., MÜSSIG K. Clinical, laboratory and imaging findings in Castleman’s disease – The subtype decides. Blood Rev. 2018; 32(3):225-234
  12. ERIC OKSENHENDLER, Protocole National de Diagnostic et de Soins (PNDS) Maladie de Castleman, Centre de Reference de la Maladie de Castleman (CRMdC)
  13. BARANZELLI A., AKKAD R., BOUCHINDHOMME B., TACELLI N., DELOURME J., DHALLUIN X., et al. La maladie de Castleman : observations inhabituelles et revue de la littérature. Revue de Pneumologie Clinique.2013, 69(1) : 55–59.
  14. V. MEIGNIN., M. PARRENS. La maladie de Castleman : aspects anatomopathologiques. La Revue de Médecine Interne, 2022; 43(10): 10S10-10S16.
  15. PALMIC, P., BRUNEAU, J., CANIONI, D., BRIERE, J., & JO MOLINA, T. Maladie de Castleman multicentrique idiopathique : comment faire le diagnostic ? Revue Francophone Des Laboratoires, 2020(518), 52–57.
  16. BORIE, R., RIQUET, M., DANEL, C., CRESTANI, B., MORDANT, P. Maladie de Castleman médiastinale : mise au point. Revue de Pneumologie Clinique, 2013; 69(6) : 354–357.
  17. BARKER R, KAZMI F, BOWER M. Imaging in multicentric Castleman’s disease. J HIV Ther. 2008; 13(3):72-4.
  18. BARKER R., KAZMI F., STEBBING J., NGAN S., CHINN R., NELSON M., et al. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease. Eur J Nucl Med Mol Imaging. 2009;36(4): 648-52.
  19. A. GONZALEZ GARCIA., W.A. SIFUENTES GIRALDO., MARIA AHIJON LANA., JOSE LUIS PATIER DE LA PEÑA. Autoimmune manifestations in patients with multicentric Castleman’s disease, Annals of the Rheumatic Diseases. 2014; 73(2) : 308.2-308.
  20. KOJIMA M., NAKAMURA S., MORISHITA Y., ITOH H, YOSHIDA K., OHNO Y., et al. Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases. Pathol Int. 2000; 50 (4):304–312.
  21. KOJIMA M., MOTOORI T., ASANO S., NAKAMURA S. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. Pathol Res Pract. 2007;203(6): 423-31.
  22. DE MARCHI G., DE VITA S., FABRIS M., SCOTT CA., FERRACCIOLI G. Systemic connective tissue disease complicated by Castleman’s disease: report of a case and review of the literature. Haematologica. 2004;89(4).
  23. SOULIER J., GROLLET L., OKSENHENDLER E., CACOUB P., CAZALS-HATEM D, BABINET P., et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86(4):1276-80.
  24. V. MEIGNIN., M. PARRENS. La maladie de Castleman: aspects anatomopathologiques. La Revue de Médecine Interne. 2022; 43(10): 10S10-10S16.
  25. LATOUR S. Natural killer T cells and X-linked lymphoproliferative syndrome. Curr Opin Allergy Clin Immunol. 2007;7(6):510-4.
  26. VÉRONIQUE MEIGNIN., JULIEN CALVANI., ERIC OKSENHENDLER. La maladie de Castleman. Annales de Pathologie.2023;43 (1): 13-24.
  27. VIALLARD JF., RORIZ M, PARRENS M., BONNOTTE B. Diagnostics différentiels de la maladie de Castleman. Rev Med Interne.2022;43(10S1):10S17-10S25.
  28. DISPENZIERI A., FAJGENBAUM DC. Overview of Castleman disease. Blood. 2020; 135(16):1353-1364.
  29. OKSENHENDLER E., BOULANGER E., GALICIER L., DU MQ., DUPIN N., DISS TC., et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7):2331-6.
  30. ISHII T., TATEKAWA T., KOSETO M., ISHII M., KOBAYASHI H., KOIKE M., et al. A case of multicentric Castleman’s disease demonstrating severe eosinophilia and enhanced production of interleukin-5. Eur J Haematol. 2003;70(2):115-8.
  31. DHINGRA H, SONDHI D, FLEISCHMAN J, AYINLA R, CHAWLA K, ROSNER F. Castleman’s disease and superior vena cava thrombi: a rare presentation and a review of the literature. Mt Sinai J Med. 2001;68(6):410-6.
  32. VAN RHEE F., GREENWAY A., STONE K. Treatment of Idiopathic Castleman Disease. Hematol Oncol Clin North Am. 2018;32(1):89-106.
  33. VAN RHEE F., VOORHEES P., DISPENZIERI A., FOSSÅ A., SRKALOVIC G., IDE M., et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115-2124.
  34. VAN RHEE F., CASPER C., VOORHEES PM., FAYAD LE., GIBSON D., KANHAI K., et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: A prespecifed, openlabel, extension analysis of two trials. Lancet Haematol. 2020;7(3): e209-e217.
  35. TALAT N., SCHULTE KM. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16(9):1316-24.
DOI: https://doi.org/10.2478/rjim-2023-0028 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Language: English
Page range: 20 - 32
Submitted on: Apr 4, 2023
|
Published on: Mar 23, 2024
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Imen Chabchoub, Raida Ben Salah, Rim Kallel, Mouna Snoussi, Feten Frikha, Sameh Marzouk, Tahya Sellami Boudawara, Zouhir Bahloul, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.